SYRS News and Press, Syros Pharmaceuticals Inc. From 01/15/20

Gainers: XPO   +15.6% . OSMT   +15.1% . SYRS   +3.1% . SAVE   +2.1% . CRSP   +1.9% . More news on: XPO Logistics, Inc., Osmotica Pharmaceuticals plc, Syros Pharmaceuticals, Inc., Stocks on the move, , Read more ...

Shares of Syros Pharmaceuticals (NASDAQ: SYRS) are soaring today, up by 15.7% as of 11:04 a.m. EST, after the company announced that Mark Alles is joining its board of directors. Alles previously served as CEO of Celgene prior to its acquisition by Bristol-Myers Squibb . The appointment of...

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Mark Alles to the Company’s Board of Directors. Mr. Alles is a recognized biopharmaceutical executive with a proven record of building...

CAMBRIDGE, Mass. , Dec. 19, 2019 /PRNewswire/ --   Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a new viral vector platform based...

Gainers:  Inpixon (NASDAQ: INPX ) +68% . More news on: Inpixon, Mirum Pharmaceuticals, Inc., YayYo, Inc., Stocks on the move, Read more ...

Syros Pharmaceuticals (NASDAQ: SYRS ) ( +6%  premarket) and Global Blood Therapeutics (NASDAQ: GBT ) ( -6%  premarket) will collaborate to discover, develop and commercialize new treatments for sickle cell disease and beta thalassemia. More news on: Syros Pharmaceuticals, Inc.,...

YayYo (NASDAQ: YAYO ) +39%  on entering into a new fleet partnership with LMP Automotive Holdings. More news on: YayYo, Inc., Solid Biosciences Inc., ASLAN Pharmaceuticals Limited, Stocks on the move, Read more ...

Balance Sheet Strengthened to Support Pipeline Advancement and Oxbryta™ (voxelotor) Commercialization SOUTH SAN FRANCISCO, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it has entered into a $150 million loan ag...

Collaboration Combines GBT’s Therapeutic Area Leadership with Power of Syros’  Gene Control Platform to Find New Medicines to Induce Fetal Hemoglobin Syros to Receive $20 Million Upfront, Three Years of Preclinical Research Funding  and Milestone Payments ...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has discovered and validated a novel fetal hemoglobin repressor, Nuclear Factor I X (NFIX), using its gene control platform. The finding sheds light on h...